In this study, we tested single-agent PDX and 6-TG as well as in combination to treat MTAP+/+ (Molt4) and MTAP−/− (CEM) T-cell ALL cell lines and xenografts. This evidence concerns the gene MTAP and acute lymphoblastic leukemia.